ABBV Jan 2021 70.000 put

OPR - OPR Delayed Price. Currency in USD
-0.2000 (-4.65%)
As of 3:46PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.3000
Expire Date2021-01-15
Day's Range4.0000 - 4.1700
Contract RangeN/A
Open InterestN/A
  • Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

    Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

    Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

  • 4 Big Drugmakers to Bet on After a Great Earnings Season

    4 Big Drugmakers to Bet on After a Great Earnings Season

    Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

  • Financial Times

    Credit market fears of downgrades have not materialised

    Like a lapsing gym membership, companies’ commitments to go on a debt diet this year have been showing signs of waning. from bond investors to help fund its $83bn acquisition of Allergan, pushing its total debt outstanding close to $100bn and making it one of the most indebted companies in the world. of drugstore Walgreens Boots Alliance by private equity firm KKR — a deal that could involve another borrowing splurge.

  • Seth Klarman Exits Allergan, Buys 3 New Positions in 3rd Quarter

    Seth Klarman Exits Allergan, Buys 3 New Positions in 3rd Quarter

    Baupost manager reports quarterly portfolio Continue reading...

  • MarketWatch

    Exicures shares up on Allergan partnership

    Shares of Exicure are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan to develop treatments for hair loss disorders. Exicure will receive an upfront payment of $25 million. In addition, it can receive milestone payments up to $97.5 million per R&D program and up to $265 million per commercial program. Allergan's portfolio has long been known for top-selling beauty brands like the medical fillers Botox and Juvéderm. Its $63 billion acquisition by AbbVie is expected to close early next year. Exicure stock is down 30.51% year-to-date, while the S&P 500 has risen 23%.


    Beware of Runs on Bond Funds

    In a less favorable market, however, bond fund investors could get hurt—not so much by worsening fundamentals, but the funds’ difficulty to meet redemptions in an illiquid market. As much as 50% of the assets in high-yield bond funds and 15% of assets of all fixed-income funds could be vulnerable to a liquidity shortfall in the event of heavy investor redemptions. “There are more risks to open-end bond funds than people are willing to acknowledge,” says Mark Grant, chief global strategist B. Riley FBR.


    AbbVie Sold $30 Billion in Bonds, and Two More Numbers to Know

    You may have heard that number cited recently as the value of an asteroid called 16 Psyche . If humans ever manage to mine the asteroid, a flood of space-gold would completely crater the terrestrial market. All that extra supply would cause today’s gold price to plummet.

  • Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?

    Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?

    On Oct. 15, Johnson & Johnson (NYSE:JNJ), the healthcare giant, reported Q3 earnings and revenue that beat analysts' average expectations. Yet, over the past 12 months, JNJ stock is down about 9%.Source: Alexander Tolstykh / Now many investors are wondering whether the company may end the year on a high note. In the next few weeks, I expect Johnson & Johnson shares to trade mostly between a range of $125 and $135. Long-term investors may view any upcoming weakness in the JNJ stock price as an opportunity to buy the shares. Analyzing JNJ's Recent EarningsWith a market cap of $347 billion, Johnson & Johnson, the healthcare giant, is currently number 37 on the Fortune 500 list. JNJ 's third-quarter revenue rose 1.9% year-over-year to $20.7 billion. Its earnings per share, excluding certain items, came in at $2.12, versus analysts' average estimate of $2.01.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Tech Stocks to Buy for the Rest of 2019 The company has a broad-based business model with a global reach. It operates in three segments that provide it with diversified sources of revenue, earnings and cash flow: * Pharmaceutical, which contributes more than 50% of JNJ's pretax profits * Consumer * Medical DevicesJNJ's pharmaceutical division markets treatments for immunology, cardiovascular and metabolic diseases, pulmonary hypertension, infectious diseases and cancer.Several of its well-known consumer brands include Aveeno, Band-Aid, Johnson's Baby, Listerine, Neutrogena, Rogaine, Tylenol and Zyrtec.Finally,its medical devices business develops and markets products and solutions for surgery, orthopedics, and vision.Although about 60% of Johnson &Johnson's revenue is U.S.-based, its overseas operations in general and its emerging market businesses in particular are proving to be important growth catalysts for JNJ. The Legal Woes of Johnson & JohnsonPharmaceutical industry firms often face legal challenges. At present, Johnson & Johnson is facing literally thousands of lawsuits.For example, in the summer, the Federal Trade Commission issued civil subpoenas to the company in an effort to determine whether JNJ had violated antitrust laws with Remicade, its rheumatoid arthritis drug.In August, Johnson and Johnson made the news when an Oklahoma judge found it guilty of helping to fuel the state's opioid crisis by aggressively marketing painkillers. JNJ is also facing various lawsuits regarding its talc-based baby powder.Recent research by Theresa Gabaldon of George Washington University Law School discusses in detail the "ballooning of pharmaceutical advertising with correlative increases in the prescriptions written for various mental and other ailments" within the industry.Professor Gabaldon further states that "Purdue Pharma led off in the 1990s by heavily advertising OxyContin as non-addictive--a claim that clearly was untrue." AbbVie (NYSE:ABBV), Johnson & Johnson, and Pfizer (NYSE:PFE) "also conducted aggressive advertising campaigns for their proprietary opioids. These campaigns, which were directed at physicians, resulted in $11 billion from opioid sales alone in 2010."In the long-run, lawsuits and fines do not necessarily dent the fundamental metrics of pharma companies much. However, in the short-term, investors understandably get spooked by the uncertainty created by lawsuits. Other Long-Term Factors to ConsiderOne of the challenges faced by JNJ and other drug companies is falling sales as the patents of blockbuster drugs expire, enabling much cheaper, competing generic drugs to be sold.Therefore, the pressure to innovate and diversify is part of the reality of managing a global pharma leader like Johnson & Johnson. And in JNJ's case, diversification has been the company's competitive advantage. As one segment faces headwinds, the others usually help propel the company forward.The forward price-earnings ratio of JNJ stock stands at 14.5 and is lower than many of its peers. Many investors would cbe comfortable paying more than that for a strong business like Johnson & Johnson.Meanwhile, Johnson & Johnson stock also has a dividend yield of 2.9%. The conglomerate has raised its dividend each year for over half a century. And dividends tend to create a "price floor" for coveted stocks such as JNJ. What Technical Charts IndicateNo investor has a crystal ball that can predict the markets' next move. However, analyzing the recent price action of JNJ stock may give us an indication of what to expect in the weeks ahead.In 2019 JNJ stock has fallen 1.6%. Its 52-week range has been $121.00 (Dec. 24, 2018) - $148.99 (Dec. 4, 2018).JNJ's short-term charts are painting a mixed picture and suggest that JNJ stock is likely to trade within a range. While long-term investors would like to see JNJ stock stay over $135, short-term traders are likely to keep the shares between $125 and $135.I do not expect Johnson & Johnson stock to reach any new highs until we have more clarity on the full ramification of several of its legal challenges.In recent weeks, the stock has found support around the $125 level. Therefore, I'd consider buying the shares if they fall toward or even below first $125 and then $120. The Bottom Line on JNJ StockThe company's diversification enables JNJ stock to withstand economic cycles more effectively. No matter what the economy does, consumers will buy the products of many of its strong brands, and Johnson & Johnson will likely have industry-leading market share in many areas.I remain bullish on the long-term outlook of Johnson and Johnson stock. However, in the short-term, JNJ might exhibit weakness.Therefore, investors may consider staying on the sidelines on JNJ if they do not currently have a position in the shares.Alternatively, investors who already own the shares may consider hedging their positions. As for hedging strategies, covered calls with a Jan. 17 expiry could be appropriate.Finally, any short-term decline in these shares may create better entry points for long-term investors who do not yet own JNJ stock.As of this writing, Tezcan Gecgil hold PFE covered calls (Nov. 15 expiry). More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks to Buy for the Rest of 2019 * 7 Biotech Stocks to Buy With Plenty of Power in the Pipeline * 5 Stocks to Buy That Are Set for Monster Growth in 2020 The post Should Investors Add Johnson & Johnson Stock to Their Shopping Lists? appeared first on InvestorPlace.

  • AbbVie Takes on Debt to Buy Allergan

    AbbVie Takes on Debt to Buy Allergan

    The $30 billion corporate loan is intended to finance the acquisition of Allergan Continue reading...


    AbbVie’s $30 Billion Bond Sale Was Wall Street’s Biggest This Year

    Investors were willing to pay up on Tuesday to buy the fourth-biggest corporate bond sale on record. To finance the acquisition, AbbVie sold $30 billion of bonds, in what was also the biggest corporate bond sale this year.


    Abbott Labs Chooses an Insider to Be Its New CEO

    Miles White, who has led the business since 1999, will be succeeded by Robert Ford, president and chief operating officer of the pharmaceutical and medical-devices company.


    Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

    Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.

  • PR Newswire

    AbbVie Prices $30 Billion of Senior Unsecured Notes

    NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie Inc. (ABBV) ("AbbVie") announced today that it has priced its previously announced private offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $30 billion (collectively, the "Notes"). AbbVie expects that the closing of the Offering will occur on November 21, 2019, subject to the satisfaction of customary closing conditions.

  • AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition

    AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition

    (Bloomberg) -- AbbVie Inc. sold $30 billion of bonds to help finance its acquisition of Allergan Plc as investors flocked to buy a piece of the largest debt sale this year. Demand for the notes was strong with the order book peaking at $77 billion.The drug maker capitalized on some of the cheapest borrowing costs of the year, with risk premiums over Treasuries at the lowest level since October 2018. That should encourage more borrowers to come forward, with investment-grade syndicate desks projecting another $17 billion in sales this week on top of AbbVie’s expected offering.Read more: IG ANALYSIS: AbbVie Prints $30b Through Curve; $73b Final BookAbbVie’s sale tops the chart as the biggest bond sale this year and it’s the fourth largest of all time. The offering came in 10 parts with the 30-year security yielding 1.90 percentage points above Treasuries, after initially discussing around 2.1 percentage points, according to people with knowledge of the matter, who asked not to be identified as the details are private. Investors placed about $77 billion in orders, people familiar with the order book said.AbbVie agreed to buy Allergan in June for $63 billion in one of the largest pharmaceutical deals this year. It should bring much-needed diversity to the acquirer’s line-up, as AbbVie’s cornerstone drug Humira, which treats arthritis, has been facing more competition, especially in Europe. U.S. antitrust officials are still reviewing the deal, which the companies expect will close early next year.The deal is expected to take the combined company’s debt to more than three times a measure of its earnings, credit raters have said. Still, Moody’s Investors Service has left its rating on AbbVie unchanged at two levels above speculative grade, as the transaction should generate significant free cash flow. S&P Global Ratings, however, said it will likely cut AbbVie one level to BBB+, three levels above junk.Read more: Corporations Pile Into Bond Market as Borrowing Costs DropManagement has reiterated its intention to pay down debt, to achieve a ratio of net debt to Ebitda -- earnings before interest, tax, depreciation and amortization -- of 2.5 times by the end of 2021. Further deleveraging through 2023 is possible, Chief Financial Officer Rob Michael said on an earnings call earlier this month.Morgan Stanley, Bank of America Corp. and Barclays Plc managed the bond sale, the person said.\--With assistance from Brian Smith.To contact the reporter on this story: Elizabeth Rembert in New York at erembert@bloomberg.netTo contact the editor responsible for this story: Nikolaj Gammeltoft at ngammeltoft@bloomberg.netFor more articles like this, please visit us at©2019 Bloomberg L.P.


    US Indexes End the Day Higher Tuesday

    S&P; 500 closes at 3,091.84 for a gain of 0.16% Continue reading...

  • Corporations Pile Into Bond Market as Borrowing Costs Drop

    Corporations Pile Into Bond Market as Borrowing Costs Drop

    (Bloomberg) -- Floodgates have opened in the corporate bond market as issuers capitalize on some of the cheapest funding costs of the year.Credit risk premiums have been tightening as investors pour money into corporate bond funds. That’s encouraging companies to borrow, with AbbVie Inc. looking to price the year’s largest sale Tuesday, and at least 10 new deals in the junk-bond market.It all adds to a bullish outlook as recession fears have abated amid stronger economic data and progress in U.S.-China trade talks, Bank of America Corp. strategists led by Hans Mikkelsen said in a report Friday. Investors expect spreads to tighten further in the next three months, but could widen over the longer-term, the strategists said, citing a November survey.With that in mind, issuers are looking to get in now while the getting’s good. Since the Federal Reserve lowered rates for a third consecutive time last month, Treasury yields have been rising as investors perceive the cutting to be done for now. Companies may be concerned that rates are only rising from here, said Ken Monaghan, co-director of high yield at Amundi Pioneer.And with most of third-quarter earnings done, and largely better than feared, equity markets have been supportive for corporate spreads, said Nicholas Elfner, co-head of research at Breckinridge Capital Advisors.“That gives you comfort that the market is relatively healthy,” Elfner said. “There’s still good demand out there for high quality names.”Investment-grade spreads are hovering at 105 basis points over Treasuries, the lowest level since October 2018. High-yield premiums meanwhile came in 16 basis points last week alone, and should rally further alongside rising stocks and oil prices. High-grade funds have seen inflows in all but one of the last 23 weeks, and high-yield funds, with the exception of a small outflow last week, had drawn in money in the three prior weeks, according to Refinitiv Lipper.AbbVie is borrowing $30 billion to help fund its purchase of Allergan Plc -- which could catapult this week’s high-grade sales to $45 billion, double last week’s total. High-yield issuers, most of which are refinancing debt, are contributing to what will the busiest day for supply in three months.“As the cost of debt remains low, you’ll see issuers rush to beat the holiday slowdown and join the party to issue,” said Lon Erickson, a portfolio manager from Thornburg Investment Management.(Updates with AbbVie deal size in the penultimate paragraph)\--With assistance from Natalie Harrison and Elizabeth Rembert.To contact the reporter on this story: Molly Smith in New York at msmith604@bloomberg.netTo contact the editors responsible for this story: Nikolaj Gammeltoft at, Christopher DeRezaFor more articles like this, please visit us at©2019 Bloomberg L.P.

  • PR Newswire

    New Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting

    - In SELECT-AXIS 1, RINVOQ™ (upadacitinib; 15 mg, once-daily) achieved the primary endpoint of ASAS40 response in adult patients with active ankylosing spondylitis (AS) at 14 weeks versus placebo - ...

  • The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

    The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

    The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

  • AbbVie Rises 3%

    AbbVie Rises 3% - AbbVie (NYSE:ABBV) rose by 3.02% to trade at $88.25 by 11:54 (16:54 GMT) on Tuesday on the NYSE exchange.

  • Financial Times

    AbbVie sells $30bn of bonds to finance Allergan takeover

    The US pharmaceuticals group AbbVie sealed one of the largest US corporate bond deals on record on Tuesday to finance its $83bn takeover of rival Allergan. AbbVie borrowed $30bn from investors clamouring ...


    AbbVie Eyes Up to $28 Billion Bond Sale to Finance Allergan Deal: Report

    The bond deal could become one of the largest as the North Chicago biopharma pushes ahead with plans to acquire Allergan, Bloomberg reported.

  • Top Research Reports for Toyota, Netflix & AbbVie

    Top Research Reports for Toyota, Netflix & AbbVie

    Top Research Reports for Toyota, Netflix & AbbVie

  • Mario Gabelli Continues to Buy AbbVie, Axalta

    Mario Gabelli Continues to Buy AbbVie, Axalta

    9 High Conviction Stocks for GAMCO Investors Continue reading...

  • AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL

    AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL

    AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.


    Psst! Want the Secret to Picking Winning Stocks? Keep Reading.

    A new report identifies free cash flow divided by enterprise value as the best predictor of stock-price performance.